FDA Scolds Merck About Conditions At Pa. Plant

Law360, New York (May 1, 2008, 12:00 AM EDT) -- Following a nearly two-month inspection of a Merck & Co. Inc. plant in Pennsylvania, the U.S. Food and Drug Administration sent the company a warning letter this week outlining what it calls “significant objectionable conditions” at the plant.

The violations are described by the FDA as “inadequate investigations of deviations and failure to maintain production and process controls,” including instances in which unnecessary fibers ended up in vaccine vials.

Nevertheless, the FDA says on its Web site that it “does not believe that the issues identified...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.